Full Text Journal Articles by
Author Angelo Avogaro

Advertisement

Find full text journal articles






Hematopoietic and non-hematopoietic p66Shc differentially regulates stem cell traffic and vascular response to ischemia in diabetes.

Mattia Albiero, Marianna D'Anna, Benedetta Maria Bonora, Gaia Zuccolotto, Antonio Rosato, Marco Giorgio, Elisabetta Iori, Angelo Avogaro, Gian Paolo Fadini,

<h4>Aims</h4>Peripheral artery disease (PAD) is a severe complication of diabetes, characterized by defective traffic of hematopoietic stem/progenitor cells (HSPCs). We examined the hematopoietic versus non-hematopoietic role of p66Shc in regulating HSPC traffic and blood flow recovery after ischemia in diabetic mice.<h4>Results</h4>Using streptozotocin-induced diabetes, chimeric mice with GFP+ bone marrow (BM), ... Read more >>

Antioxid Redox Signal (Antioxidants & redox signaling)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study.

Mario Luca Morieri, Giovanni Targher, Annunziata Lapolla, Michele D'Ambrosio, Federica Tadiotto, Mauro Rigato, Vera Frison, Agostino Paccagnella, Natalino Simioni, Angelo Avogaro, Gian Paolo Fadini,

<h4>Aims</h4>Metabolic dysfunction-associated fatty liver disease (MAFLD) is common in people with type 2 diabetes (T2D) and can progress to advanced fibrosis and cirrhosis. In this retrospective study, we explored the longitudinal changes in markers of hepatic steatosis and fibrosis during T2D treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs).<h4>Methods</h4>We analysed observational ... Read more >>

Nutr Metab Cardiovasc Dis (Nutrition, metabolism, and cardiovascular diseases : NMCD)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

A Deep Learning Approach to Predict Diabetes' Cardiovascular Complications From Administrative Claims.

Enrico Longato, Gian Paolo Fadini, Giovanni Sparacino, Angelo Avogaro, Lara Tramontan, Barbara Di Camillo,

People with diabetes require lifelong access to healthcare services to delay the onset of complications. Their disease management processes generate great volumes of data across several domains, from clinical to administrative. Difficulties in accessing and processing these data hinder their secondary use in an institutional setting, even for highly desirable ... Read more >>

IEEE J Biomed Health Inform (IEEE journal of biomedical and health informatics)
[2021, 25(9):3608-3617]

Cited: 0 times

View full text PDF listing >>



Performance Assessment Across Different Care Settings of A Novel Heart Failure Hospitalisation Risk Score For Type 2 Diabetes Patients Developed Using Administrative Claims Only

Alessandro Guazzo, Enrico Longato, Giovanni Sparacino, Bruno Franco-Novelletto, Maurizio Cancian, Massimo Fusello, Lara Tramontan, Alessandro Battaggia, Angelo Avogaro, Gian Paolo Fadini, Barbara Di Camillo,

Predicting the risk of cardiovascular complications, in particular heart failure hospitalisation (HHF), can improve the management of type 2 diabetes (T2D). Most predictive models proposed so far rely on clinical data not available at the higher Institutional level. Therefore, it is of interest to assess the risk of HHF in ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies.

Enrico Longato, Benedetta Maria Bonora, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini,

<h4>Aims</h4>We compared cardiovascular outcomes of patients with type 2 diabetes (T2D) receiving sodium glucose cotransporter-2 inhibitors (SGLT2i) or dipeptidyl peptidase-4 inhibitors (DPP4i) under routine care.<h4>Methods</h4>From an administrative claims database of >5.2M citizen, we identified patients with T2D who initiated SGLT2i or DPP4i from 2014 to 2018. Patients were matched by ... Read more >>

Diabetes Res Clin Pract (Diabetes research and clinical practice)
[2021, 179:109024]

Cited: 0 times

View full text PDF listing >>



Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society.

Raffaele Napoli, Angelo Avogaro, Gloria Formoso, Salvatore Piro, Francesco Purrello, Giovanni Targher, Agostino Consoli,

Patients with type 2 diabetes mellitus (T2DM) show an increased risk of cardiovascular diseases (CVD) and mortality. Many factors are implicated in the pathogenesis of CVD in patients with T2DM. Among the factors involved, chronic hyperglycemia and the cluster of CVD risk factors, such as dyslipidemia, hypertension, and obesity, play ... Read more >>

Nutr Metab Cardiovasc Dis (Nutrition, metabolism, and cardiovascular diseases : NMCD)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial.

Benedetta Maria Bonora, Mattia Albiero, Mario Luca Morieri, Roberta Cappellari, Francesco Ivan Amendolagine, Marta Mazzucato, Alberto Zambon, Elisabetta Iori, Angelo Avogaro, Gian Paolo Fadini,

<h4>Aim/hypothesis</h4>In two large RCTs, fenofibrate reduced the progression of diabetic retinopathy. We investigated whether fenofibrate increases circulating haematopoietic stem/progenitor cells (HSPCs), which have vascular properties and have been shown to protect from retinopathy.<h4>Methods</h4>We conducted a 12 week parallel-group RCT comparing fenofibrate vs placebo. Patients with diabetic retinopathy and without other conditions ... Read more >>

Diabetologia (Diabetologia)
[2021, 64(10):2334-2344]

Cited: 0 times

View full text PDF listing >>



Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.

Mario Luca Morieri, Valentina Perrone, Chiara Veronesi, Luca Degli Esposti, Margherita Andretta, Mario Plebani, Gian Paolo Fadini, Saula Vigili de Kreutzenberg, Angelo Avogaro,

<h4>Background</h4>This cross-sectional study aimed to identify actionable factors to improve LDL-cholesterol target achievement and overcome underuse of lipid-lowering treatments in high- or very-high-cardiovascular risk patients.<h4>Methods</h4>We evaluated healthcare records of 934,332 subjects from North-Italy, including subjects with available lipid profile and being on statin treatments up to December 2018. A 6-month-period ... Read more >>

Cardiovasc Diabetol (Cardiovascular diabetology)
[2021, 20(1):144]

Cited: 0 times

View full text PDF listing >>



Where diabetes care meets cardiovascular research: our cardiovascular perspective at a Centre devoted to diabetes research and care.

Gian Paolo Fadini, Saula Vigili de Kreutzenberg, Angelo Avogaro,

Eur Heart J (European heart journal)
[2021, 42(25):2417-2419]

Cited: 0 times

View full text PDF listing >>



High prolactin levels in dihydropteridine reductase deficiency: A sign of therapy failure or additional pathology?

Nicola Vitturi, Livia Lenzini, Concetta Luisi, Miryam Carecchio, Giorgia Gugelmo, Francesco Francini-Pesenti, Angelo Avogaro,

We report the case of a 22-year-old man with a diagnosis of dihydropteridine reductase (DHPR) deficiency who progressively developed movement disorders and epilepsy. Despite L-Dopa supplementation the patient continued to show high prolactin levels, with a discrepancy between the neurological clinical picture and the hormonal biochemical levels. For this reason, ... Read more >>

JIMD Rep (JIMD reports)
[2021, 61(1):48-51]

Cited: 0 times

View full text PDF listing >>



Managing diabetes in diabetic patients with COVID: where do we start from?

Angelo Avogaro, Benedetta Bonora, Gian Paolo Fadini,

<h4>Aims</h4>COVID-19 has and still is sweeping away the national health systems worldwide. In this review, we sought to determine the evidence base proofs on the antidiabetic treatment capable to reduce the risk of COVID-19-related mortality.<h4>Methods</h4>We have performed a systematic search of published articles using PubMed, and EMBASE from March 2020 ... Read more >>

Acta Diabetol (Acta diabetologica)
[2021, 58(11):1441-1450]

Cited: 1 time

View full text PDF listing >>



Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation.

Lucrezia Ferrario, Fabrizio Schettini, Angelo Avogaro, Chiara Bellia, Federico Bertuzzi, Graziella Bonetti, Antonio Ceriello, Marcello Ciaccio, Massimiliano Corsi Romanelli, Elena Dozio, Luca Falqui, Angela Girelli, Antonio Nicolucci, Gianluca Perseghin, Mario Plebani, Umberto Valentini, Martina Zaninotto, Silvana Castaldi, Emanuela Foglia,

<h4>Purpose</h4>To investigate the glycated albumin (GA) introduction implications, as an add-on strategy to traditional glycemic control (Hb1Ac and fasting plasma glucose - FPG) instruments, considering insulin-naïve individuals with type 2 diabetes mellitus (T2DM), treated with oral therapies.<h4>Methods</h4>A Health Technology Assessment was conducted in Italy, as a multi-dimensional approach useful to ... Read more >>

Clinicoecon Outcomes Res (ClinicoEconomics and outcomes research : CEOR)
[2021, 13:453-464]

Cited: 0 times

View full text PDF listing >>



A simple way to spotlight hidden heart failure in type 2 diabetes?

Gian Paolo Fadini, Angelo Avogaro,

Eur J Heart Fail (European journal of heart failure)
[2021, 23(7):1094-1096]

Cited: 0 times

View full text PDF listing >>



Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis.

Mattia Albiero, Serena Tedesco, Francesco Ivan Amendolagine, Marianna D'Anna, Ludovica Migliozzi, Gaia Zuccolotto, Antonio Rosato, Roberta Cappellari, Angelo Avogaro, Gian Paolo Fadini,

The mechanisms by which sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in people with diabetes are incompletely understood. Recent studies show that SGLT2i may increase the levels of circulating cells with vascular regenerative capacity, at least in part by lowering glycemia. In this study, we used mice with streptozotocin-induced ... Read more >>

Diabetes (Diabetes)
[2021, 70(8):1767-1779]

Cited: 1 time

View full text PDF listing >>



SGLT2 inhibitors: Do we need other evidences?

Angelo Avogaro,

Eur J Intern Med (European journal of internal medicine)
[2021, 87:18-19]

Cited: 0 times

View full text PDF listing >>



PAR-4/Ca2+-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes.

Alessandra Giannella, Giulio Ceolotto, Claudia Maria Radu, Arianna Cattelan, Elisabetta Iori, Andrea Benetti, Fabrizio Fabris, Paolo Simioni, Angelo Avogaro, Saula Vigili de Kreutzenberg,

<h4>Background</h4>Patients with type 2 diabetes (T2DM) have a prothrombotic state that needs to be fully clarified; microparticles (MPs) have emerged as mediators and markers of this condition. Thus, we investigate, in vivo, in T2DM either with good (HbA1c ≤ 7.0%; GGC) or poor (HbA1c > 7.0%; PGC) glycemic control, the circulating levels of MPs, ... Read more >>

Cardiovasc Diabetol (Cardiovascular diabetology)
[2021, 20(1):77]

Cited: 2 times

View full text PDF listing >>



The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique.

Giuseppina Russo, Matteo Monami, Gianluca Perseghin, Angelo Avogaro, Pasquale Perrone Filardi, Michele Senni, Claudio Borghi, Aldo P Maggioni,

<h4>Introduction</h4>There is no consensus on the optimal therapeutic approach to adopt in patients with newly diagnosed type 2 diabetes mellitus (T2DM) to prevent cardiovascular disease (CVD). The study aimed to gather an expert consensus on the hypoglycemic treatment and CV risk management in patients with newly diagnosed T2DM through the Delphi ... Read more >>

Diabetes Ther (Diabetes therapy : research, treatment and education of diabetes and related disorders)
[2021, 12(5):1445-1461]

Cited: 0 times

View full text PDF listing >>



Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives.

Federico Boscari, Angelo Avogaro,

Type 1 diabetes mellitus imposes a significant burden of complications and mortality, despite important advances in treatment: subjects affected by this disease have also a worse quality of life-related to disease management. To overcome these challenges, different new approaches have been proposed, such as new insulin formulations or innovative devices. ... Read more >>

Rev Endocr Metab Disord (Reviews in endocrine & metabolic disorders)
[2021, 22(2):217-240]

Cited: 1 time

View full text PDF listing >>



Lung Ultrasound Patterns and Clinical-Laboratory Correlates during COVID-19 Pneumonia: A Retrospective Study from North East Italy.

Riccardo Senter, Federico Capone, Stefano Pasqualin, Lorenzo Cerruti, Leonardo Molinari, Elisa Fonte Basso, Nicolò Zanforlin, Lorenzo Previato, Alessandro Toffolon, Caterina Sensi, Gaetano Arcidiacono, Davide Gorgi, Renato Ippolito, Enrico Nessi, Pietro Pettenella, Andrea Cellini, Claudio Fossa, Eleonora Vania, Samuele Gardin, Andi Sukthi, Dora Luise, Maria Teresa Giordani, Mirko Zanatta, Sandro Savino, Vito Cianci, Andrea Sattin, Anna Maria, Andrea Vianello, Raffaele Pesavento, Sandro Giannini, Angelo Avogaro, Roberto Vettor, Gian Paolo Fadini, Alois Saller,

<h4>Background and aim</h4>Lung ultrasound (LUS) is a convenient imaging modality in the setting of coronavirus disease-19 (COVID-19) because it is easily available, can be performed bedside and repeated over time. We herein examined LUS patterns in relation to disease severity and disease stage among patients with COVID-19 pneumonia.<h4>Methods</h4>We performed a ... Read more >>

J Clin Med (Journal of clinical medicine)
[2021, 10(6):]

Cited: 1 time

View full text PDF listing >>



Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies.

Angelo Avogaro, Francesco Barillà, Franco Cavalot, Agostino Consoli, Massimo Federici, Massimo Mancone, Stefania Paolillo, Roberto Pedrinelli, Gianluca Perseghin, Pasquale Perrone Filardi, Roberto Scicali, Gianfranco Sinagra, Carmen Spaccarotella, Ciro Indolfi, Francesco Purrello,

<h4>Aim</h4>This review represents a joint effort of the Italian Societies of Cardiology (SIC) and Diabetes (SID) to define the state of the art in a field of great clinical and scientific interest which is experiencing a moment of major cultural advancements, the cardiovascular risk management in type 2 diabetes mellitus.<h4>Data ... Read more >>

Nutr Metab Cardiovasc Dis (Nutrition, metabolism, and cardiovascular diseases : NMCD)
[2021, 31(6):1671-1690]

Cited: 0 times

View full text PDF listing >>



SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.

Benedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro, Gian Paolo Fadini,

<h4>Background</h4>Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS).<h4>Methods</h4>We mined the FAERS from 2014q1 to 2019q4 to compare AF reporting ... Read more >>

Cardiovasc Diabetol (Cardiovascular diabetology)
[2021, 20(1):39]

Cited: 2 times

View full text PDF listing >>



Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes.

Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini,

<h4>Aims</h4>Glucagon like peptide-1 (GLP-1) receptor agonists (GLP-1RA) are effective to control type 2 diabetes (T2Ds) and can protect from adverse cardiovascular outcomes. GLP-1RA are based on the human GLP-1 or the exendin-4 sequence. We compared cardiovascular outcomes of patients with T2D who received human-based or exendin-based GLP-1RA in routine clinical ... Read more >>

Eur J Prev Cardiol (European journal of preventive cardiology)
[2021, 28(1):22-29]

Cited: 0 times

View full text PDF listing >>



Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care.

Benedetta Maria Bonora, Mauro Rigato, Vera Frison, Michele D'Ambrosio, Federica Tadiotto, Annunziata Lapolla, Natalino Simioni, Agostino Paccagnella, Angelo Avogaro, Gian Paolo Fadini,

<h4>Aims</h4>We evaluated de-intensification of basal-bolus insulin (BBI) after initiation of a GLP-1 receptor agonist (GLP-1RA) under routine care.<h4>Research design and methods</h4>This retrospective, multicenter study conducted at outpatient clinics in North-East Italy collected data on patients with T2D on BBI who initiated a GLP-1RA. Patients were divided according to whether they ... Read more >>

Diabetes Res Clin Pract (Diabetes research and clinical practice)
[2021, 173:108686]

Cited: 0 times

View full text PDF listing >>



Efficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown.

Federico Boscari, Sara Ferretto, Ambra Uliana, Angelo Avogaro, Daniela Bruttomesso,

<h4>Background</h4>Starting March 2020 the Italian Government imposed a lockdown to limit the spread of SARS-CoV-2. During lockdown outpatient visits were limited and telemedicine (TM) was encouraged.<h4>Methods</h4>We retrospectively analyzed data from continuous or flash glucose monitoring systems shared through different cloud systems during the lockdown by subjects with type 1 diabetes ... Read more >>

Nutr Diabetes (Nutrition & diabetes)
[2021, 11(1):1]

Cited: 5 times

View full text PDF listing >>



Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial.

Peter Rossing, Jorma Strand, Angelo Avogaro, Michael Becka, Friederike Kanefendt, Christiane Otto,

<h4>Background</h4>The protease chymase generates multiple factors involved in tissue remodelling including angiotensin II (Ang II) and has been implicated in the pathophysiology of diabetic kidney disease (DKD). This study investigated the effects of the chymase inhibitor fulacimstat on albuminuria in patients with Type II diabetes mellitus and a clinical diagnosis ... Read more >>

Nephrol Dial Transplant (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.051 s